Active Implants said today it launched a new site at in its Venus trial looking to investigate its NUsurface investigational meniscus implant for treating persistent knee pain caused by deteriorating or injured meniscal cartilage.
The NUsurface is made from medical grade plastic and is designed to not require fixation to bone or soft tissue by mimicking the function of the natural meniscus, Active Implants said.
“There are limited options for patients who experience persistent knee pain following meniscus surgery. Damage to the meniscus with loss of meniscal function can lead to activity-related pain in the near-term and, in some cases, to arthritis in the long-term,” Dr. William Garrett Jr. of the Duke University School of Medicine, which serves as a site in the new trial, said in prepared remarks.
The Venus trial is slated to enroll 130 patients between 30 and 75 with pain after medial meniscus surgery at orthopedic centers in the U.S., Europe and Israel, Durham, N.C.-based Active Implants said.
Yesterday, Active Implants said it launched a 2nd clinical trial to evaluate its NUsurface meniscus implant designed to be meniscus replacement for patients looking to avoid or delay total knee replacement procedures.
Active Implant’s SUN trial is slated to enroll 120 patients with persistent knee pain caused by injury or deterioration at up to 20 sites, the Memphis, Tenn.-based company said.
The device has an investigative device exemption in the U.S. and has been cleared for clinical use in Europe and Israel, the company said.
At DeviceTalks Boston, Tyler Shultz will give attendees an inside look at Theranos and how he was able to sound the alarm after he realized the company was falling apart. Shultz will take attendees behind the story that everyone is talking about: the rise and fall of Elizabeth Holmes and her diagnostic company, Theranos.
Join Shultz and 1,000+ medical device professionals at the 8th annual DeviceTalks Boston.